{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:44:32Z","timestamp":1768823072770,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1983,6,1]],"date-time":"1983-06-01T00:00:00Z","timestamp":423273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1983,6,1]],"date-time":"1983-06-01T00:00:00Z","timestamp":423273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1983,6]]},"DOI":"10.1007\/bf00172077","type":"journal-article","created":{"date-parts":[[2004,8,15]],"date-time":"2004-08-15T04:54:44Z","timestamp":1092545684000},"page":"173-179","source":"Crossref","is-referenced-by-count":12,"title":["Phase I trial of aclacinomycin-A"],"prefix":"10.1007","volume":"1","author":[{"given":"Chatchada","family":"Karanes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John D.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"Samson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine B.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis A.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence H.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF00172077_CR1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.7164\/antibiotics.28.830","volume":"28","author":"T Oki","year":"1975","unstructured":"Oki T, Matusuzawa Yl, Yoshimato A, Numata K, Kitamura I, Hori S, Takamatsu A, Umezawa H, Ishizuka M, Naganawa H, Suda H, Haraada M, Takeuchi T: New antitumor antibiotics, aclacinomycin-A and B. J Antibiot (Tokyo) 28:830\u2013834, 1975","journal-title":"J Antibiot (Tokyo)"},{"key":"BF00172077_CR2","unstructured":"Aclacinomycin-A (NSC 208 734). Clinical brochure, NCI, July, 1979"},{"key":"BF00172077_CR3","first-page":"685","volume":"68","author":"S Hori","year":"1977","unstructured":"Hori S, Shirai M, Hirano S, Oki T, Inui T, Tsukagoshi S, Ishizuka M, Takeuchi T, Umezawa H: Antitumor activity of new anthracycline antibodies, aclacinomycin-A and its analogs and their toxicity. Gann 68:685\u2013690, 1977","journal-title":"Gann"},{"key":"BF00172077_CR4","first-page":"21","volume":"2","author":"T Oki","year":"1978","unstructured":"Oki T, Iguchi H, Hori S, Inui T, Takeuchi T, Umezawa H: New anthracycline antibiotic aclacinomycin-A: action and metabolism. Proc 12th Int Cancer Cong 2:21\u201322, 1978","journal-title":"Proc 12th Int Cancer Cong"},{"key":"BF00172077_CR5","first-page":"259","volume":"1","author":"G Mathe","year":"1978","unstructured":"Mathe G, Bayssas M, Gouveia J, Dantchev D, Ribaud P, Machover D, Misset J, Schwarzenberg L, Jasmin C, Bayat M: Preliminary results of a Phase II trial of aclacinomycin in acute leukemia and lymphosarcoma: An oncostatic anthracycline that is rarely cardiotoxic and induces no alopecia. Cancer Chemother Pharmacol 1:259\u2013262, 1978","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF00172077_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/978-3-642-81565-2_4","volume":"76","author":"T Oki","year":"1980","unstructured":"Oki T, Takeuchi T, Oka S, Umezawa H: New anthracycline antibiotic aclacinomycin-A: Experimental studies and correlations with clinical trials. Recent Results Cancer Research 76:21\u201340, 1980","journal-title":"Recent Results Cancer Research"},{"key":"BF00172077_CR7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.7164\/antibiotics.34.52","volume":"34","author":"Y Ogasawara","year":"1981","unstructured":"Ogasawara Y, Masuda Y, Goto S, Mori S, Oki T: High performance liquid chromatographic determination of aclacinomycin-A and its related compounds. II. Reverse phase HPLC determination of aclacinomycin-A and its metabolites in biological fluids using fluorescence detection. J Antibiot 34:52\u201357, 1981","journal-title":"J Antibiot"},{"key":"BF00172077_CR8","unstructured":"Sedman A, Wagner J: Autoan Manual. J. Wagner, Upjohn Center for Clinical Pharmacology, The University of Michigan Medical Center, Ann Arbor, MI 48109"},{"key":"BF00172077_CR9","first-page":"75","volume":"4","author":"H Furue","year":"1977","unstructured":"Furue H, Furkawa K, Nakao I, Harashima S, Yokoyama T, Kanko T, Fujii A: Clinical information of aclacinomycin-A. Cancer Chemother (Japan) 4:75\u201379, 1977","journal-title":"Cancer Chemother (Japan)"},{"key":"BF00172077_CR10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/cpt1973144part1592","volume":"14","author":"R Benjamin","year":"1973","unstructured":"Benjamin R, Riggs C, Bachur N: Pharmacokinetics and metabolism of adriamycin in man. Clin Pharmacol Ther 14:592\u2013600, 1973","journal-title":"Clin Pharmacol Ther"},{"key":"BF00172077_CR11","first-page":"1416","volume":"37","author":"R Benjamin","year":"1977","unstructured":"Benjamin R, Riggs C, Bachur N: Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res 37:1416\u20131420, 1977","journal-title":"Cancer Res"},{"key":"BF00172077_CR12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/cpt197112196","volume":"12","author":"D Alberts","year":"1971","unstructured":"Alberts D, Bachur N, Holtzman J: The pharmacokinetics of daunomycin in man. Clin Pharmacol Ther 12:96\u2013104, 1971","journal-title":"Clin Pharmacol Ther"},{"key":"BF00172077_CR13","first-page":"295","volume-title":"Carminomycin in Anthracyclines: Current Status and New Development","author":"S Reich","year":"1980","unstructured":"Reich S, Crooke S: Carminomycin in Anthracyclines: Current Status and New Development. S Crooke and S Reich (eds), Academic Press, New York, 1980, pp 295\u2013313"},{"key":"BF00172077_CR14","first-page":"244","volume":"31","author":"B Seyland-Jones","year":"1982","unstructured":"Seyland-Jones B, Deesen P, Wittes R, Young C: High pressure liquid chromatography methodology and human plasma pharmacokinetics of 4\u2032-epi-doxorubicin and its metabolites. Clin Pharmacol Ther 31:244, 1982","journal-title":"Clin Pharmacol Ther"},{"key":"BF00172077_CR15","doi-asserted-by":"crossref","first-page":"178","DOI":"10.7164\/antibiotics.31.178","volume":"31","author":"G Cassinelli","year":"1978","unstructured":"Cassinelli G, Grein A, Masi P, Suarato A, Bernardi L, Arcamone F, Di Marco A, Casazza A, Pratesi G, Soranzo C: Preparation and biological evaluation of 4\u20130-demethyl-daunorubicin (carminomycin I) and of its 13 dihydro derivatives. J Antibiot (Tokyo) 31:178\u2013184, 1978","journal-title":"J Antibiot (Tokyo)"},{"key":"BF00172077_CR16","first-page":"491","volume":"19","author":"W Meriwether","year":"1971","unstructured":"Meriwether W, Bachur N, Gee M: Inhibition of DNA and RNA metabolism by daunorubicin (D1) and its major metabolite (D2) in L1210 mouse leukemia (abstract) Clin Res 19:491, 1971","journal-title":"Clin Res"},{"key":"BF00172077_CR17","first-page":"813","volume":"60","author":"A Weiss","year":"1976","unstructured":"Weiss A, Metter G, Fletcher W, Wilson W, Grage T, Ramirez G: Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 60:813\u2013822, 1976","journal-title":"Cancer Treat Rep"},{"key":"BF00172077_CR18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-96-2-133","volume":"96","author":"S Legha","year":"1982","unstructured":"Legha S, Benjamin R, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen S, Blumenschein G, Freireich E: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Int Med 96:133\u2013139, 1982","journal-title":"Ann Int Med"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00172077\/fulltext.html","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00172077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00172077\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00172077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00172077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:24:09Z","timestamp":1678559049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00172077"}},"subtitle":["A clinical and pharmacokinetic study"],"short-title":[],"issued":{"date-parts":[[1983,6]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1983,6]]}},"alternative-id":["BF00172077"],"URL":"https:\/\/doi.org\/10.1007\/bf00172077","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,6]]}}}